Editas Medicine, Inc.
A biotech company that develops treatments for serious diseases by editing genes with CRISPR, a molecular tool that snips and rewrites DNA. Founded in 2013 in Cambridge, Massachusetts, it was started by pioneers of the field including Jennifer Doudna and Feng Zhang, and its name comes from the Latin word "edit." Its medicines aim at inherited conditions such as blood disorders and cardiovascular disease.
Sold 1.86M
Sold 859.0K
Sold 5.9K
Bought 35.0K
Bought 2.04M
Bought 100.0K
Bought 2.04M
Sold 236.1K
Granted 411.8K · Sold 163.5K
Granted 166.2K · Sold 32.8K
Granted 8.0K · Sold 8.0K
Granted 139.2K · Sold 26.4K
Granted 124.8K · Sold 18.2K
Granted 73.0K · Bought 35.0K · Sold 32.1K
Granted 57.8K · Sold 11.3K
Bought 67.7K
Granted 85.0K · Sold 23.5K
Granted 73.5K · Sold 7.9K
Granted 52.2K · Sold 8.4K
Granted 109.6K · Sold 92.8K
Granted 24.2K · Sold 1.6K
Sold 3.0K
Bought 4.0K
Granted 153.8K · Sold 142.5K
Granted 76.0K · Sold 76.0K
Granted 25.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bitterman KevinDirector · 14 transactions | — | 42.84Mas of May 2017 | — | — | 1.86M |
| Polaris Venture Management Co. VI, L.L.C. +2 co-filers10% owner · 13 transactions | — | 42.59Mas of Dec 2016 | — | — | 859.0K |
| Afeyan Noubar +4 co-filers10% owner · 9 transactions | — | 7.97Mas of Aug 2016 | — | — | — |
| Starr Kevin P10% owner · 1 transaction | — | 3.91Mas of Sep 2016 | — | — | 5.9K |
| Levin Mark J +5 co-filers10% owner · 2 transactions | — | 3.91Mas of Aug 2016 | — | — | — |
| Nikolic BorisDirector · 2 transactions | — | 2.68Mas of Jun 2017 | — | 35.0K | — |
| bng0, LLC10% owner · 1 transaction | — | 2.65Mas of Feb 2016 | — | — | — |
| Halvorsen Ole Andreas +6 co-filersFormer 10% Owner · 9 transactions | — | 1.97Mas of Feb 2015 | — | 2.04M | — |
| Deerfield Management Co +5 co-filersReporting owner · 3 transactions | — | 1.81Mas of Feb 2016 | — | 100.0K | — |
| VGE III Portfolio Ltd. +5 co-filersFormer 10% Owner · 9 transactions | — | 1.28Mas of Feb 2016 | — | 2.04M | — |
| Bosley KatrinePresident and CEO, Director · 51 transactions | — | 1.20Mas of Jan 2019 | — | — | 236.1K |
| O'Neill Gilmore NeilCEO, Director · 16 transactions | — | 248.3K | 411.8K | — | 163.5K |
| Mei BaisongEVP, CHIEF MEDICAL OFFICER · 11 transactions | — | 133.4Kas of Dec 2024 | 166.2K | — | 32.8K |
| Glucksmann AlexandraChief Operating Officer · 7 transactions | — | 118.8Kas of Mar 2017 | 8.0K | — | 8.0K |
| Lucera ErickEVP, CHIEF FINANCIAL OFFICER · 5 transactions | — | 112.7Kas of Mar 2025 | 139.2K | — | 26.4K |
| Robertson MichelleEVP, CHIEF FINANCIAL OFFICER · 19 transactions | — | 106.6Kas of May 2023 | 124.8K | — | 18.2K |
| Mullen James CCEO, Director · 6 transactions | — | 75.9Kas of Jan 2022 | 73.0K | 35.0K | 32.1K |
| Eaton BruceEVP, CBO AND CTO · 26 transactions | — | 74.8Kas of Dec 2023 | 57.8K | — | 11.3K |
| Hopfield JessicaDirector · 4 transactions | — | 67.7Kas of May 2024 | — | 67.7K | — |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER · 11 transactions | — | 67.3K | 85.0K | — | 23.5K |
| Shearman Mark SEVP, CHIEF SCIENTIFIC OFFICER · 5 transactions | — | 65.6Kas of Feb 2023 | 73.5K | — | 7.9K |
| Collins CynthiaCEO · 7 transactions | — | 43.8Kas of Feb 2021 | 52.2K | — | 8.4K |
| Albright CharlesEVP/Chief Scientific Officer · 25 transactions | — | 24.9Kas of Dec 2020 | 109.6K | — | 92.8K |
| Michaels Lisa AnneEVP/Chief Medical Officer · 3 transactions | — | 22.7Kas of Dec 2021 | 24.2K | — | 1.6K |
| Parison AmySVP, Chief Financial Officer · 6 transactions | — | 15.0K | — | — | 3.0K |
| Cox Gerald FrankChief Medical Officer · 1 transaction | — | 4.0Kas of Jun 2017 | — | 4.0K | — |
| Cole Douglas G.Director · 2 transactions | — | 3.2Kas of Aug 2017 | — | — | — |
| Hack Andrew A. F.Chief Financial Officer · 46 transactions | — | 0as of Feb 2019 | 153.8K | — | 142.5K |
| Myer VickeshChief Technology Officer · 47 transactions | — | 0as of Mar 2019 | 76.0K | — | 76.0K |
| Abrams Judith RChief Medical Officer · 1 transaction | — | 0as of Oct 2019 | 25.0K | — | — |
| Borisy AlexisDirector · 1 transaction | — | 0as of Feb 2016 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +715.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.